{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T00:07:09Z","timestamp":1759018029740,"version":"3.44.0"},"reference-count":12,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aaojournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.ophtha.2018.12.041","type":"journal-article","created":{"date-parts":[[2019,2,22]],"date-time":"2019-02-22T07:02:54Z","timestamp":1550818974000},"page":"425-427","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Drug Costs, Effectiveness, and Kids in the Crossfire: Adalimumab in Juvenile Idiopathic Arthritis-Associated Uveitis"],"prefix":"10.1016","volume":"126","author":[{"given":"Russell N.","family":"Van Gelder","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ophtha.2018.12.041_bib1","article-title":"Childhood Arthritis and Rheumatology Research Alliance consensus treatment plans for juvenile idiopathic arthritis-associated and idiopathic chronic anterior uveitis","author":"Angeles-Han","year":"2018","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"8","key":"10.1016\/j.ophtha.2018.12.041_bib2","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1136\/annrheumdis-2018-213131","article-title":"Consensus-based recommendations for the management of uveitis associated with juvenile idiopathic arthritis: the SHARE initiative","volume":"77","author":"Constantin","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.ophtha.2018.12.041_bib3","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.ophtha.2013.09.048","article-title":"Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders","volume":"121","author":"Levy-Clarke","year":"2014","journal-title":"Ophthalmology"},{"issue":"10","key":"10.1016\/j.ophtha.2018.12.041_bib4","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1056\/NEJMoa1509852","article-title":"Adalimumab in patients with active noninfectious uveitis","volume":"375","author":"Jaffe","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"17","key":"10.1016\/j.ophtha.2018.12.041_bib5","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1056\/NEJMoa1614160","article-title":"Adalimumab plus methotrexate for uveitis in juvenile idiopathic arthritis","volume":"376","author":"Ramanan","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"10050","key":"10.1016\/j.ophtha.2018.12.041_bib6","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/S0140-6736(16)31339-3","article-title":"Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial","volume":"388","author":"Nguyen","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ophtha.2018.12.041_bib7","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.ophtha.2018.09.043","article-title":"Cost-effectiveness analysis of adalimumab for the treatment of uveitis associated with juvenile idiopathic arthritis","volume":"126","author":"Hughes","year":"2019","journal-title":"Ophthalmology"},{"issue":"35","key":"10.1016\/j.ophtha.2018.12.041_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta20350","volume":"20","author":"Stevenson","year":"2016","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.ophtha.2018.12.041_bib9","doi-asserted-by":"crossref","first-page":"e22","DOI":"10.1016\/j.ophtha.2018.12.004","article-title":"Re: Hughes et al.: Cost-effectiveness analysis of adalimumab for the treatment of uveitis associated with juvenile idiopathic arthritis","volume":"126","author":"Lightman","year":"2019","journal-title":"Ophthalmology"},{"issue":"11","key":"10.1016\/j.ophtha.2018.12.041_bib10","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1001\/archopht.122.11.1659","article-title":"Health-related quality of life at age 10 years in very low-birth-weight children with and without threshold retinopathy of prematurity","volume":"122","author":"Quinn","year":"2004","journal-title":"Arch Ophthalmol"},{"issue":"1","key":"10.1016\/j.ophtha.2018.12.041_bib11","doi-asserted-by":"crossref","first-page":"8","DOI":"10.7326\/M16-0713","article-title":"Triple therapy versus biologic therapy for active rheumatoid arthritis: a cost-effectiveness analysis","volume":"167","author":"Bansback","year":"2017","journal-title":"Ann Intern Med"},{"issue":"8","key":"10.1016\/j.ophtha.2018.12.041_bib14","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1001\/jama.2016.11237","article-title":"The high cost of prescription drugs in the United States: origins and prospects for reform","volume":"316","author":"Kesselheim","year":"2016","journal-title":"JAMA"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642018333335?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642018333335?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T14:07:02Z","timestamp":1758982022000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161642018333335"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":12,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["S0161642018333335"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2018.12.041","relation":{},"ISSN":["0161-6420"],"issn-type":[{"type":"print","value":"0161-6420"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug Costs, Effectiveness, and Kids in the Crossfire: Adalimumab in Juvenile Idiopathic Arthritis-Associated Uveitis","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ophtha.2018.12.041","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.ophtha.2018.09.043","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 by the American Academy of Ophthalmology","name":"copyright","label":"Copyright"}]}}